金蝉益肾通络方通过HIF-1α-PINK1-Parkin通路改善糖尿病肾病线粒体功能障碍与凋亡
本研究探讨金蝉益肾通络方(JCYSTL)对糖尿病肾病(DN)的肾脏保护机制。采用单侧肾切除联合低剂量链脲佐菌素腹腔注射的DN大鼠模型及高糖加缺氧诱导的HK-2细胞,发现JCYSTL降低尿白蛋白、血肌酐、尿素氮和尿酸,升高肌酐清除率,并通过稳定HIF-1α激活PINK1/Parkin介导的线粒体自噬,改善线粒体功能、抑制凋亡。
要点
- JCYSTL改善DN大鼠肾功能指标,降低尿白蛋白、血肌酐、尿素氮和尿酸,升高肌酐清除率。
- JCYSTL通过稳定HIF-1α激活PINK1/Parkin介导的线粒体自噬保护肾小管。
- PINK1敲低后JCYSTL对线粒体膜电位、Bax和Bcl-2的调节作用消失。
核心结论
- JCYSTL通过稳定HIF-1α激活PINK1/Parkin介导的线粒体自噬,保护糖尿病条件下的肾小管免于线粒体功能障碍和凋亡。
研究设计与样本
- 采用单侧肾切除联合低剂量链脲佐菌素腹腔注射的DN大鼠模型和高糖加缺氧诱导的HK-2细胞。
主要发现
- JCYSTL治疗显著降低DN大鼠尿白蛋白、血肌酐、血尿素氮和尿酸水平,并升高肌酐清除率。
- 含JCYSTL的含药血清提高高糖/缺氧诱导HK-2细胞的线粒体膜电位,改善线粒体呼吸链复合物I、III、IV活性。
- 含药血清降低凋亡细胞百分比和促凋亡蛋白Bax表达,增加抗凋亡蛋白Bcl-2表达。
- JCYSTL治疗组HK-2细胞中PINK1、Parkin和LC3-II积累增加,P62水平降低。
- PINK1敲低后,JCYSTL对Parkin、LC3-II和P62的改善作用消失,对Bax的抑制及对MMP和Bcl-2的促进作用也消失。
临床怎么用
- JCYSTL可能作为糖尿病肾病的一种有前景的治疗选择,其肾脏保护机制与调控HIF-1α/PINK1/Parkin介导的线粒体自噬相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The JinChan YiShen TongLuo (JCYSTL) formula, a traditional Chinese medicine (TCM), has been used clinically for decades to treat diabetic nephropathy (DN). TCM believes that the core pathogenesis of DN is "kidney deficiency and collateral obstruction," and JCYSTL has the effect of "tonifying kidney and clearing collateral," thus alleviating the damage to kidney structure and function caused by diabetes. From the perspective of modern medicine, mitochondrial damage is an important factor in DN pathogenesis. Our study suggests that the regulation of mitophagy and mitochondrial function by JCYSTL may be one of the internal mechanisms underlying its good clinical efficacy. AIM OF THE STUDY: This study aimed to investigate the mechanisms underlying the renoprotective effects of JCYSTL. MATERIALS AND METHODS: Unilateral nephrectomy combined with low-dose streptozotocin intraperitoneally injected in a DN rat model and high glucose (HG) plus hypoxia-induced HK-2 cells were used to explore the effects of JCYSTL on the HIF-1α/mitophagy pathway, mitochondrial function and apoptosis. RESULTS: JCYSTL treatment significantly decreased albuminuria, serum creatinine, blood urea nitrogen, and uric acid levels and increased creatinine clearance levels in DN rats. In vitro, medicated serum containing JCYSTL formula increased mitochondrial membrane potential (MMP); improved activities of mitochondrial respiratory chain complexes I, III, and IV; decreased the apoptotic cell percentage and apoptotic protein Bax expression; and increased anti-apoptotic protein Bcl-2 expression in HG/hypoxia-induced HK-2 cells. The treatment group exhibited increased accumulation of PINK1, Parkin, and LC3-II and reduced P62 levels in HG/hypoxia-induced HK-2 cells, whereas in PINK1 knockdown HK-2 cells, JCYSTL did not improve the HG/hypoxia-induced changes in Parkin, LC3-II, and P62. When mitophagy was impaired by PINK1 knockdown, the inhibitory effect of JCYSTL on Bax and its promoting effect on MMP and Bcl-2 disappeared. The JCYSTL-treated group displayed significantly higher HIF-1α expression than the model group in vivo, which was comparable to the effects of FG-4592 in DN rats. PINK1 knockdown did not affect HIF-1α accumulation in JCYSTL-treated HK-2 cells exposed to HG/hypoxia. Both JCYSTL and FG-4592 ameliorated mitochondrial morphological abnormalities and reduced the mitochondrial respiratory chain complex activity in the renal tubules of DN rats. Mitochondrial apoptosis signals in DN rats, such as increased Bax and Caspase-3 expression and apoptosis ratio, were weakened by JCYSTL or FG-4592 administration. CONCLUSION: This study demonstrates that the JCYSTL formula activates PINK1/Parkin-mediated mitophagy by stabilizing HIF-1α to protect renal tubules from mitochondrial dysfunction and apoptosis in diabetic conditions, presenting a promising therapy for the treatment of DN.
引用
- Qiyan Zheng, Zhang X, Guo J, et al. JinChan YiShen TongLuo Formula ameliorate mitochondrial dysfunction and apoptosis in diabetic nephropathy through the HIF-1α-PINK1-Parkin pathway. J Ethnopharmacol. 2024. PMID: 38325670. doi:10.1016/j.jep.2024.117863
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。